Keyphrases
Clinical Trials
100%
Angiotensin II (Ang II)
100%
Equivalent Dose
100%
Vasodilatory Shock
100%
Vasopressor Dose
100%
Placebo
45%
Vasopressors
18%
Standard of Care
18%
Placebo Groups
18%
Drug Use Initiation
18%
January 2015
9%
High Dose
9%
Disease Severity
9%
Potential Gains
9%
Mean Arterial Pressure
9%
Poor Outcome
9%
Clinical Trial Data
9%
Serious Adverse Events
9%
Phase III Clinical Trial
9%
Trial Data
9%
Trial Registration
9%
High Output
9%
Vasopressor Agents
9%
Vasopressor Support
9%
Output Shocks
9%
Medicine and Dentistry
Hypertensive Factor
100%
Noradrenalin
100%
Angiotensin II
100%
Post-Hoc Analysis
100%
Equivalent Dose
100%
Clinical Trial
100%
Placebo
63%
Adverse Event
9%
Drug Megadose
9%
Low Drug Dose
9%
Mean Arterial Pressure
9%
Amikacin
9%
Antihypotensive Agent
9%
Arm
9%
Diseases
9%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Hypertensive Factor
100%
Noradrenalin
100%
Angiotensin II
100%
Placebo
63%
Adverse Event
9%
Hypertensive Agent
9%
Amikacin
9%
Diseases
9%
Neuroscience
Norepinephrine
100%
Angiotensin II
100%
Placebo
63%
Antihypotensive Agent
9%